Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blood pressure drug shown to cut stroke, death risks in common form of hypertension

25.09.2002


Losartan tops beta blocker in patients with ’high top number’ blood pressure



A drug that reduces high blood pressure in people with a form of the disease that’s common later in life also cuts their risk of stroke and death, and does it better than another hypertension drug, a new study finds.

In the Sept. 25 issue of the Journal of the American Medical Association, an international team of researchers report that patients over age 55 who took a drug called losartan had a significantly lower combined rate of cardiovascular death, stroke and heart attack than similar patients taking an older drug called atenolol.


The results are from a substudy of the Losartan Intervention for Endpoint Reduction in Hypertension, or LIFE, study, co-led by physicians from the University of Michigan.

All 1,326 men and women in the study had isolated systolic hypertension, or ISH, a form of high blood pressure in which the "top number" in the reading is too high, but the bottom number is normal. The pumping chambers of the patients’ hearts were also enlarged, a condition called left ventricular hypertrophy caused by hypertension.

ISH is the most common form of high blood pressure in middle-aged people and the elderly, but is much less likely to be controlled by medications. One in four Americans, about 50 million people, have some form of hypertension, many with no symptoms. Left uncontrolled, high blood pressure can damage the heart, kidneys and blood vessels, and lead to stroke, heart attack and heart failure.

In the study, the combined rate of cardiovascular death, stroke and heart attack in patients taking losartan was 25 percent lower than the risk for those taking atenolol. The rate of cardiovascular-related deaths was 46 percent lower for losartan patients, their rate of stroke was 40 percent lower, and their overall death rate was 28 percent lower. They also had a lower rate of new diabetes diagnosis during the study. Heart attack rates were similar between the two groups.

Both groups experienced a similar drop in blood pressure, and more than 40 percent of both groups were able to reduce their blood pressure to around 140/90 mm Hg.

"This is the first demonstration that a treatment can reduce illness and death in ISH patients better than another treatment that is equally good at reducing blood pressure," says author and LIFE study co-leader Stevo Julius, M.D., Sc.D. "The finding of a 40 percent reduction in stroke is especially important, because of stroke’s role as a major cause of death and disability in people with hypertension." Julius is the Frederick G.L. Huetwell Professor of Hypertension and professor of Physiology at the U-M Medical School, and a member of the U-M Cardiovascular Center.

The study was funded by Merck & Co., which markets losartan by the name Cozaar.

The results, Julius continues, are further enhanced by the fact that patients experienced fewer negative side effects on losartan better than they did on atenolol. "This favorable combination of better prevention and higher tolerability may facilitate the choice of losartan as the first-line blood pressure medication in patients with ISH," he says.

U-M adjunct professor of internal medicine and hypertension specialist Sverre Kjeldsen, M.D., Ph.D., who is also chief of cardiology at the Ullevaal University Hospital in Oslo, Norway, is the study’s lead author.

The new LIFE results add to previous evidence of losartan’s ability to cut the combined risk of cardiovascular death, stroke and heart attack by 13 percent, and stroke risk by 25 percent, in people over age 55 with all forms of hypertension. Those results, from the full LIFE group of more than 9,000 patients in seven countries, were published in March by the LIFE study group.

Losartan, introduced in 1995, is a kind of drug called an angiotensin II antagonist, which blocks the effects of a substance called angiotensin II that increases blood pressure by constricting blood vessels and causing water to be retained.

The LIFE study, which began in 1995, pitted losartan against atenolol, a member of the beta blocker class of drugs, for a study that ended in September, 2001.

Patients in the study were aged 55 to 80 years, with systolic (top) blood pressure readings between 160 and 200 and left ventricular hypertrophy confirmed by an electrocardiogram. They were randomized to either drug, then followed for four or more years with regular visits and increased dosing of the drug toward a goal of a systolic reading of 140.

The study was designed to be prospective, multicenter, multinational, double-blind, double-dummy, randomized, active-controlled and parallel group to ensure the most reliable results. Participants were predominantly white, reflecting the populations of many of the countries from which they were drawn.

High blood pressure is defined as systolic pressure (top number) of 140 or higher, and/or diastolic pressure (bottom number) of 90 or higher for most people. Isolated systolic hypertension is defined as when the top reading is greater than or equal to 140 and the bottom number is less than 90. All blood pressure readings are given in millimeters of mercury, or mm Hg.

In addition to medications, people with ISH and other forms of high blood pressure should talk with their physicians about how exercise, weight loss, stopping smoking and cutting salt in their diets can help lower blood pressure and reduce their risks of cardiovascular diseases, diabetes and kidney disease.


###
Julius has served as a consultant for Merck and other pharmaceutical companies, and Kjeldsen has received honoraria from Merck and other companies. Several other co-authors are Merck employees.

Kara Gavin | EurekAlert!
Further information:
http://www.scandinaviancri.se/life/results/home.shtm
http://www.med.umich.edu/cvc/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>